Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

Rheumatology (Oxford). 2016 Jul;55(7):1337-9. doi: 10.1093/rheumatology/kew040. Epub 2016 Apr 22.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antiphospholipid Syndrome / immunology*
  • Catastrophic Illness / therapy
  • Complement Activation / immunology*
  • Complement Inactivating Agents / therapeutic use
  • Female
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • eculizumab